Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial

2 September 2024 (14:00 - 14:40)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Cristiane Lauretti

University of Sao Paulo, Sao Paulo (Brazil)

4 More presentations in this session

Presentation thumbnail

HFpEF and glycemic variability: GHIDD Trial

Professor G. Fazio (Palermo, IT)

Abstract Slides Video

Presentation thumbnail

Telomere length across spectrum of metabolic health.

Associate Professor T. Osadnik (Zabrze, PL)

Abstract Slides Video

Presentation thumbnail

Spermidine attenuates left ventricular dysfunction in estrogen deprived aging rats through mitigating lipid peroxidation and mitochondrial dysfunction

Doctor C. Maneechote (Chiang Mai, TH)

Abstract Slides Video

Presentation thumbnail

Elevated levels of plasma inactive stromal cell derived factor-1a predict long-term adverse outcomes in diabetic patients with coronary artery disease

Assistant Professor Y. Chikata (Tokyo, JP)

Abstract Slides Video

Access the full session

Session thumbnail

Metabolic syndrome and heart disease (2)

The Event

Event poster

ESC Congress 2024

2 September 2024 14:00 CET

You may be interested in

Congress Presentation

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

Congress Presentation

The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

Congress Presentation

Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources